Peptic Ulcer. Chronic Inflammation?

0
39

Abstract

Purpose

The correlation of fibromyalgia syndrome (FMS) with peptic ulcer disease (PUD) is unclear. We therefore conducted a cohort study to investigate whether FMS is correlated with an increased risk of PUD.

Methods

In this study, we established an FMS cohort comprising 26068 patients aged more than 20 years who were diagnosed with FMS from 2000 to 2011. Furthermore, we established a control cohort by randomly choosing 104269 people without FMS who were matched to the FMS patients by gender, age, and index year. All patients were free of PUD at the baseline. Cox proportional hazard regressions were performed to compute the hazard ratio of PUD after adjustment for demographic characteristics and comorbidities.

Results

The prevalence of comorbidities was significantly higher in the FMS patients than in the controls. The incidence of PUD was 29.8 and 19.4 per 1000 person-years in the FMS and control cohorts, respectively. In addition, the FMS cohort exhibited a 1.40-fold higher risk of PUD (95% confidence interval = 1.35–1.45) compared with the control cohort. After control for confounding factors, the medications (selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, and antidepressants) taken by the FMS patients did not increase the risk of PUD.

Conclusion

FMS patients exhibit a higher risk of PUD than that of patients without FMS.

Introduction

Currently, fibromyalgia syndrome (FMS) is a complex condition affecting patients and can represent a diagnostic challenge for physicians. It is characterized as a pain processing disorder with several distinct secondary symptoms and is associated with low quality of life. [] With the multitude of conditions contributing to FMS development, the exact cause of the disorder is unclear. However, it has been hypothesized that FMS is caused by an extensive list of factors, ranging from persistent inflammation and immunologic and muscular abnormalities to triggering [] and maintenance factors. []

Approximately 50% of FMS patients often exhibit other illnesses, such as gastroesophageal reflux disease (GERD), irritable bowel syndrome, and other gastrointestinal disorders. [] Among these illnesses, food sensitivities are an essential determinant of inflammation that might be associated to FMS pain. This pain and inflammation can be provoked by particular foods, such as preservatives, eggs, and gluten; however, the food causing FMS symptoms differs from person to person. Until now, few studies have demonstrated which specific foods are connected to FMS pain. [] Moreover, recent studies have revealed that the severity of small intestinal bacterial outgrowth (SIBO) is correlated with FMS patients’ level of pain, indicating the significance of SIBO in FMS. [,] Furthermore, some researchers believe that FMS and gastrointestinal disorders occur in conjunction because their drivers—inflammation in the brain and gut or bacterial outgrowth in the intestines—are similar. []

The Helicobacter pylori bacterium is typically the causative agent of peptic ulcers, which are sores in the gastric lining, esophagus, or duodenum. These ulcers can also be attributed to the consistent use of nonsteroidal anti-inflammatory drugs (NSAIDs). Various classes of drugs, which often include NSAIDs, are utilized for treating FMS. However, despite their widespread use, results have shown their ineffectiveness in relieving FMS pain. [] Therefore, physicians currently prescribe drugs that affect the central nervous system, [,] targeting the origins of pain reception and slowly eliminating the use of NSAIDs in FMS treatment.

Some physicians believe that stress [] may play a role in the activity of the gut through its effect on hormones and nerves [,], although the link is yet to be confirmed. To the best of our knowledge, the epidemiological evidence for the association of FMS with the risk of PUD is still insufficient. Therefore, in this population-based study, we investigated the relationship between FMS and PUD development.

Methods

Data source

The National Health Insurance (NHI) program in Taiwan is a single-payer universal insurance program implemented on March 1, 1995, and the NHI program covers approximately 99% of the Taiwanese population. [] The National Health Insurance Administration has authorized the National Health Research Institutes (NHRI) to create an encrypted, secondary database—the National Health Insurance Research Database (NHIRD)—for research purposes. In this study, we analyzed the Longitudinal Health Insurance Database 2000 (LHID2000), which constitutes a subdataset of the NHIRD. The details of the LHID2000 are provided in previous studies. [,] Diagnoses were classified according to the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes.

Data availability statement

The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve our application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email: wt.vog.whom@uwloracts) for further assistance. Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848. All relevant data are within the paper.

Ethics statement

The NHIRD encrypts patient personal information to ensure patient privacy, and researchers are provided with anonymous identification numbers associated with the relevant claims information, including sex, date of birth, medical services received, and prescriptions. Therefore, patient consent is not required to access the NHIRD. This study was approved to fulfill the condition for exemption by the Institutional Review Board (IRB) of China Medical University (CMUH104-REC2-115-CR1). The IRB also specifically waived the consent requirement.

Study population

This study was assessed on the risk of PUD between the individual with and without FMS. FMS, characterized by widespread musculoskeletal pain and multiple tender points, was diagnosed by rheumatologists, neurologists, psychologists, physiatrists, and pain specialists with clinical accuracy, according to the American College of Rheumatology Criteria for the Classification of Fibromyalgia. [] Patients aged ≥20 years who were diagnosed with FMS (ICD-9-CM code 729.1) more than three times within 3 months were included in the FMS cohort. The index date was defined as the first diagnosis date of FMS. To establish a control cohort, patients without FMS were randomly selected and matched to the FMS patients at a 4:1 ratio by age group (every 5-year span), sex, and index date. The exclusion criteria were a history of PUD (ICD-9-CM codes 531–533) before the index date and missing information.

Outcome

The outcome of interest was a new diagnosis of PUD from 2000 to 2011. Both the FMS and control cohorts were monitored until diagnosis of PUD or until the patients were censored because of withdrawal from the NHI program or the end of 2011.

Comorbidities and medications

To evaluate the potential risk and to control for confounding factors, we included the comorbidities and medications of each patient, namely hyperlipidemia (ICD-9-CM code 272), diabetes (ICD-9-CM code 250), liver cirrhosis (ICD-9-CM codes 571.2, 571.5, and 571.6), alcohol-related illness (ICD-9-CM codes 291, 303, 305, 571.0, 571.1, 571.2, 571.3, 790.3, A215, and V11.3), hypertension (ICD-9-CM codes 401–405), depression (ICD-9-CM codes 296.2, 296.3, 300.4, and 311), anxiety (ICD-9-CM code 300.0), sleep disorder (ICD-9-CM codes 307.4 and 780.5), stroke (ICD-9-CM codes 430–438), H. pylori infection (ICD-9-CM code 041.86), GERD (ICD-9-CM codes 530.11 and 530.81), and proton pump inhibitor (PPI) and NSAID use. Furthermore, we assessed whether FMS medications, including amitriptyline, fluoxetine, duloxetine, milnacipran, meclobemide, tropisetron, pramipexole, and pregabalin, play a role in PUD outcomes.

Statistical analysis

The chi-square test was used for analyzing categorical variables, and the Student’s t test was used for analyzing continuous variables. The cumulative incidence of PUD in the FMS and control cohorts was explored using the Kaplan–Meier method, and the differences were determined using log-rank tests. The incidence density rates were calculated by dividing the number of PUD events by the total follow-up years (per 1st000 person-years). The incidence density rates of PUD for each risk factor and stratified by age, sex, comorbidity, and medications in the both cohorts were calculated. Univariable and multivariable Cox proportional hazard regression models were used to determine the risk factors for PUD, denoted as a hazard ratio (HR) with a 95% confidence interval (CI). Stratified analysis of PUD risk by age, sex, comorbidities and medications was also estimated by the Cox models. The multivariable models included all statistically significant risk factors identified in the univariable model. Data management and analyses were performed using SAS 9.4 software (SAS Institute, Cary, NC, USA). A two-tailed P value < 0.05 was considered significant.

Results

A total of 26068 FMS patients and 104269 controls were included in this study (Table 1). Most patients were aged ≤49 years (53.8%) and were women (54.6%). The mean ages of the FMS and control cohorts were 49.5 ± 16.0 and 49.0 ± 16.3 years, respectively. The comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, stroke, and GERD and NSAID use were more prevalent in the FMS cohort than in the control cohort. The average follow-up durations were 5.59 and 5.87 years in the FMS and control FMS cohorts, respectively. As shown in Fig 1, the cumulative incidence of PUD was higher in the FMS cohort than in the control cohort (log-rank test P < 0.001).

An external file that holds a picture, illustration, etc. Object name is pone.0175370.g001.jpg

Comparison of cumulative incidence of peptic ulcer disease in patients with (dashed line) and those without (solid line) fibromyalgia syndrome.

Table 1

Demographic characteristics and comorbidities in patients with and without fibromyalgia syndrome.
Non-FM cohort FM cohort
Variable N = 104269 N = 26068 p-value
Age, year 0.99
≤ 49 56100(53.8) 14025(53.8)
50–64 28020(26.9) 7005(26.9)
65+ 20149(19.3) 5038(19.3)
Mean±SD 49.0(16.3) 49.5(16.0) <0.001
Sex 0.99
Female 56972(54.6) 14243(54.6)
Male 47297(45.4) 11825(45.4)
Comorbidity
Hyperlipidemia 14314(13.7) 4900(18.8) <0.001
Diabetes 6838(6.56) 2159(8.28) <0.001
Liver cirrhosis 468(0.45) 150(0.58) 0.008
Alcohol-related illness 2148(2.06) 714(2.74) <0.001
Hypertension 24322(23.3) 7673(29.4) <0.001
Depression 2561(2.46) 1064(4.08) <0.001
Anxiety 3695(3.54) 1624(6.23) <0.001
Sleep disorder 12290(11.8) 5072(19.5) <0.001
Stroke 2633(2.53) 874(3.35) <0.001
Gastroesophageal reflux disorder 439(0.42) 168(0.64) <0.001
H. pylori infection 42(0.04) 11(0.04) 0.89
Medication
NSAID 42400(40.7) 14738(56.5) <0.001

Chi-square test;

: t test

NSAID, nonsteroidal anti-inflammatory drug

The incidence density rate of PUD was 29.8 per 1000 person-years in the FMS cohort, which was significantly higher than that in the control cohort (19.4 per 1000 person-years; Table 2). The FMS cohort exhibited a 1.40-fold higher risk of PUD compared with the control cohort (95% CI = 1.35–1.45). Compared with patients aged ≤49 years, the risk of PUD was 1.58- and 1.96-fold higher in those aged 50–64 years and ≥65 years (95% CI = 1.52–1.64 and 1.88–2.05, respectively). The risk of PUD was higher in patients with the comorbidities of hyperlipidemia [adjusted HR (aHR) = 1.22, 95% CI = 1.17–1.27], liver cirrhosis (aHR = 1.76, 95% CI = 1.48–2.09), hypertension (aHR = 1.24, 95% CI = 1.19–1.29), depression (aHR = 1.19, 95% CI = 1.09–1.29), anxiety (aHR = 1.15, 95% CI = 1.10–1.20), and sleep disorder (aHR = 1.15, 95% CI = 1.10–1.20). The aHR of PUD development was high in patients taking NSAIDs (aHR = 1.28, 95% CI = 1.24–1.33).

Table 2

Incidence and risk factors for peptic ulcer disease.
Variable Event PY Rate# Crude HR (95% CI) Adjusted HR (95% CI)
Fibromyalgia
Non-FM cohort 11879 612540 19.4 1.00 1.00
FM cohort 4337 145634 29.8 1.53(1.48, 1.58)*** 1.40(1.35, 1.45)***
Age, year
≤ 49 6258 435894 14.4 1.00 1.00
50–64 5309 198789 26.7 1.84(1.77, 1.91)*** 1.58(1.52, 1.64)***
65+ 4649 123491 37.7 2.54(2.44, 2.63)*** 1.96(1.88, 2.05)***
Sex
Female 9287 426012 21.8 1.00 1.00
Male 6929 332162 20.9 1.06(1.02, 1.09)*** 1.02(0.98, 1.05)
Comorbidity
Hyperlipidemia
No 12600 659721 19.1 1.00 1.00
Yes 3616 98453 36.7 1.88(1.81, 1.95)*** 1.22(1.17, 1.27)***
Diabetes
No 14707 715952 20.5 1.00 1.00
Yes 1509 42222 35.7 1.68(1.59, 1.77)*** 1.00(0.94, 1.06)
Liver cirrhosis
No 16088 755855 21.3 1.00 1.00
Yes 128 2319 55.2 2.43(2.04, 2.89)*** 1.76(1.48, 2.09)***
Alcohol-related illness
No 15895 746747 21.3 1.00 1.00
Yes 321 11427 28.1 1.24(1.11, 1.38)*** 1.06(0.95, 1.19)
Hypertension
No 10280 592447 17.4 1.00 1.00
Yes 5936 165727 35.8 2.02(1.96, 2.09)*** 1.24(1.19, 1.29)***
Depression
No 15610 741182 21.1 1.00 1.00
Yes 606 16992 35.7 1.63(1.51, 1.77)*** 1.19(1.09, 1.29)***
Anxiety
No 15325 734729 20.9 1.00 1.00
Yes 891 23445 38.0 1.73(1.62, 1.85)*** 1.15(1.10, 1.20)***
Sleep disorder
No 13513 676459 20.0 1.00 1.00
Yes 2703 81716 33.1 1.59(1.52, 1.65)*** 1.15(1.10, 1.20)***
Stroke
No 15665 743843 21.1 1.00 1.00
Yes 551 14331 38.5 1.72(1.58, 1.87)*** 0.97(0.89, 1.06)
Gastroesophageal reflux disorder
No 16157 756844 21.4 1.00 1.00
Yes 59 1330 44.4 1.75(1.35, 2.25)*** 1.16(0.90, 1.51)
H. pylori infection
No 16215 758066 21.4 1.00 1.00
Yes 1 108 9.25 0.36(0.05, 2.53)
Medication
NSAID
No 7853 472003 16.6 1.00 1.00
Yes 8363 286171 29.2 1.69(1.64, 1.74)*** 1.28(1.24, 1.33)***

PY, person-years;

Rate#, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR: multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, stroke, and gastroesophageal reflux disorder; and NSAID use.

***P < 0.001

Table 3 shows a comparison of PUD incidence and the Cox model-measured hazards ratio between the patients with FMS and those without FMS after stratification by age, sex, comorbidity, and medications. Regardless of stratification, the risk of PUD was higher in the FMS patients than in the controls.

Table 3

Incidence of peptic ulcer disease by age, sex, comorbidity, and medications and Cox model-measured hazard ratio for patients with fibromyalgia syndrome compared those without fibromyalgia syndrome.
Non-FM cohort FM cohort
Variables Event PY Rate# Event PY Rate# Crude HR (95% CI) Adjusted HR (95% CI)
Age, years
≤ 49 4423 351605 12.6 1835 84290 21.8 1.72(1.63, 1.82)*** 1.52(1.44, 1.61)***
50–64 3947 161146 24.5 1362 37643 36.2 1.47(1.38, 1.56)*** 1.32(1.24, 1.40)***
65+ 3509 99789 35.2 1140 23702 48.1 1.36(1.27, 1.45)*** 1.3091.22, 1.39)***
Sex
Female 6825 344075 19.8 2462 81937 30.1 1.51(1.44, 1.58)*** 1.37(1.31, 1.44)***
Male 5054 268465 18.8 1875 63697 29.4 1.56(1.48, 1.64)*** 1.45(1.37, 1.53)***
Comorbidity
No 5608 408359 13.7 1621 77476 20.9 1.5291.44, 1.61)*** 1.48(1.40, 1.56)***
Yes 6271 204181 30.7 2716 68158 39.9 1.30(1.24, 1.36)*** 1.33(1.27, 1.39)***
Medication
NSAID
No 6195 402114 15.4 1658 69890 23.7 1.53(1.45, 1.62)*** 1.50(1.42, 1.59)***
Yes 5684 210426 27.0 2679 75745 35.4 1.32(1.26, 1.39)*** 1.33(1.27, 1.39)***

PY, person-years;

Rate#, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR: multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke; and NSAID use.

Comorbidity: Patients with any one of the comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke.

***P < 0.001

Table 4 displays the results of an analysis of the effects of FMS medications on the risk of PUD compared with the control cohort. FMS patients who did not receive medications exhibited a significantly 1.48-fold higher risk of PUD (95% CI = 1.42–1.53) compared with the controls. Patients receiving meclobemide, fluoxetine, tropisetron, duloxetine, or milnacipran exhibited a significantly 1.64-fold higher risk of PUD (95% CI = 1.28–2.10) compared with the controls. FMS patients who received pregabalin, amitriptyline, or pramipexole exhibited a significantly 1.55-fold higher risk of PUD (95% CI = 1.22–1.97) compared with the controls.

Table 4

Incidence and hazard ratio of peptic ulcer disease among fibromyalgia syndrome patients with and without treatment and compared with controls.
Variables N Event PY Rate# Crude HR (95% CI) Adjusted HR (95% CI)
Non- fibromyalgia controls 104269 11879 612540 19.4 1(Reference) 1(Reference)
Fibromyalgia
Without medications 24201 4118 133790 30.8 1.58(1.52, 1.63)*** 1.48(1.42, 1.53)***
Treatment with pregabalin, amitriptyline, pramipexole 265 68 1861 36.5 1.95(1.54, 2.48)*** 1.55(1.22, 1.97)***
Treatment with meclobemide, fluoxetine, tropisetron, duloxetine, or milnacipran 261 63 1776 35.5 1.87(1.46, 2.39)** 1.64(1.28, 2.10)***

PY, person-years;

Rate#, incidence rate, per 1000 person-years; crude HR, relative hazard ratio;

adjusted HR: hazard ratio from multivariable analysis including age; sex; comorbidities of hyperlipidemia, diabetes, liver cirrhosis, alcohol-related illness, hypertension, depression, anxiety, sleep disorder, and stroke; and NSAID use.

**P < 0.01,

***P < 0.001

Discussion

This is the first study that showed the long-term risk of PUD in FMS patients by using a population-based database. Through the primary findings, our hypothesis that FMS patients have an elevated risk of PUD is proven true. At the end of the follow-up period, the cumulative frequency of PUD was higher in the FMS cohort than in the control cohort (Fig 1). The incidence density rates of PUD were 29.8 and 19.4 per 1000 person-years in the FMS and control cohorts, respectively. Moreover, the FMS cohort exhibited a 1.40-fold higher risk of PUD (95% CI = 1.35–1.45) compared with the control cohort (Table 2).

The prevalence rate of comorbidities was also compared between the FMS and control cohorts, as shown in Table 1. Comorbidities such as hyperlipidemia, diabetes, liver cirrhosis, hypertension, depression, anxiety, sleep disorder, stroke, and GERD and PPI and NSAID use were more common in the FMS cohort than in the control cohort. Although not a primary concern of the current study, certain illnesses are expected to be more prevalent in the FMS cohort. [,] Because FMS is a complex condition that is likely multifactorial, both internal and external factors may be triggers for PUD development. []

The mechanisms underlying the association of FMS with an increased risk of PUD are unclear. However, many patients reported an intestinal infection as the initial symptom of FMS; therefore, current and past infection with common intestinal pathogens (i.e., H. pylori) might induce PUD development in FMS patients. [,,] In addition, gut infection, gut inflammation, medications, stress, and trauma can induce PUD development and damage the mucosal barrier of the gastrointestinal epithelium, [] which allows unshielded molecules to enter the bloodstream (known as leaky gut syndrome). The leaky gut causes systemic inflammation and triggers immune responses, leading to a wide array of diseases, including FMS. []

The risk of PUD in FMS patients receiving medications and those not receiving medications was 1.59-fold (95% CI = 1.34–1.89) and 1.48-fold (95% CI = 1.42–1.53) higher than that in the controls. Drugs that affect serotonin levels (fluoxetine, tropisetron, duloxetine, meclobemide, and milnacipran) were shown to increase the risk of gastrointestinal problems by other investigators [], but they did not exert more adverse effects than those of other medications (pregabalin, amitriptyline, and pramipexole) in our study (aHR = 1.64 and 1.55, respectively). Our findings show that the listed drugs may not be the cause of ulcers (Table 4).

Increasing evidence has shown that bioenergetics and mitochondrial function are impaired in FMS [] and PUD [] patients. Although it is unclear whether oxidative stress is a common pathway of PUD and FMS, recent studies have shown that oxidative stress can cause the pathophysiological mechanisms that culminate in the symptoms of PUD and FMS.

This study has some limitations. First, the data extracted from the NHIRD represent only the incidents at discharge; discrepancies between medical treatments and patient diagnoses cannot be directly verified. Second, our study did not assess the severity of FMS and PUD; therefore, we cannot for certain state how the FMS severity affects the subsequent risk of PUD. Moreover, the evidence in this study may be restricted to Taiwan, because it was obtained using the claims data in the NHIRD for feasibility and practicality. Finally, the patients’ diet, exposure to smoking and alcohol, and psychological factors are not available in the NHI dataset; therefore, these factors could not be estimated when determining the PUD risk.

Conclusion

In this study, we demonstrated that FMS contributes to an elevated risk of PUD. FMS patients had a high prevalence of comorbidities, and the drugs identified that relieve psychosomatic symptoms in FMS did not increase the likelihood of ulcers. The mechanisms underlying the link between FMS and PUD are still unclear. Additional studies are required to clarify the underlying mechanisms.

 

Supporting information

S1 STROBE Checklist

Checklist of items that should be included in reports of observational studies.

(DOC)

Acknowledgments

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004); China Medical University Hospital; the Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); the NRPB Stroke Clinical Trial Consortium (MOST105-2325-B-039-003); the Tseng-Lien Lin Foundation, Taichung, Taiwan; the Taiwan Brain Disease Foundation, Taipei, Taiwan; the Katsuzo and Kiyo Aoshima Memorial Funds, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Abbreviations

CI confidence interval
FMS fibromyalgia syndrome
GERD gastroesophageal reflux disease
HR hazard ratio
ICD-9-CM International Classification of Diseases, Ninth Revision, Clinical Modification
LHID2000 Longitudinal Health Insurance Database 2000
NHIRD National Health Insurance Research Database
NSAIDs nonsteroidal anti-inflammatory drugs
PUD peptic ulcer disease
SIBO small intestinal bacterial outgrowth

Funding Statement

This study was supported in part by the Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW105-TDU-B-212-133019); China Medical University Hospital; Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037); NRPB Stroke Clinical Trial Consortium (MOST 104-2325-B-039 -005); the Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo Aoshima Memorial Funds, Japan; and CMU under the Aim for Top University Plan of the Ministry of Education, Taiwan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

Data Availability

The dataset used in this study is held by the Taiwan Ministry of Health and Welfare (MOHW). The Ministry of Health and Welfare must approve our application to access this data. Any researcher interested in accessing this dataset can submit an application form to the Ministry of Health and Welfare requesting access. Please contact the staff of MOHW (Email: wt.vog.whom@uwloracts) for further assistance. Taiwan Ministry of Health and Welfare Address: No.488, Sec. 6, Zhongxiao E. Rd., Nangang Dist., Taipei City 115, Taiwan (R.O.C.). Phone: +886-2-8590-6848.

References

1. Lauche R, Cramer H, Häuser W, Dobos G, Langhorst J. A Systematic Overview of Reviews for Complementary and Alternative Therapies in the Treatment of the Fibromyalgia Syndrome. Evid Based Complement Alternat Med. 2015;2015:610–615. [PMC free article] [PubMed]
2. Rehm SE, Koroschetz J, Gockel U, Brosz M, Freynhagen R, TÖlle TR, et al. A cross-sectional survey of 3035 patients with fibromyalgia: subgroups of patients with typical comorbidities and sensory symptom profiles. Rheumatology 2010;49:1146–1152. doi: 10.1093/rheumatology/keq066 [PubMed]
3. Erin Lawson, Marks Wallace. Fibromyalgia: clinical guideline and treatments. ISBN-978-3-319-15820-4 (eBook), Springer International publishing Switzerland 2015. pp1-192.
4. Vincent A, Whipple MO, Oh TH, Guderian JA, Barton DL, Luedtke CA. Early experience with a brief, multimodal, multidisciplinary treatment program for fibromyalgia. Pain Manag Nurs. 2013;14:228–235. doi: 10.1016/j.pmn.2011.05.001 [PMC free article] [PubMed]
5. Stisi S, Cazzola M, Buskila D, Spath M, Giamberardino MA, Sarzi-Puttini P, et al. Etiopathogenetic mechanisms of fibromyalgia syndrome. Reumatismo. 2008;60:25–35. [PubMed]
6. Lee YC, Nassikas NJ, Clauw DJ. The role of the central nervous system in the generation and maintenance of chronic pain in rheumatoid arthritis, osteoarthritis and fibromyalgia. Arthritis Res Ther. 2011;13:211 doi: 10.1186/ar3306 [PMC free article] [PubMed]
7. Woolf CJ. Central sensitization: implications for the diagnosis and treatment of pain. Pain. 2011;152: S2–15. doi: 10.1016/j.pain.2010.09.030 [PMC free article] [PubMed]
8. Masi AT. An intuitive person-centered perspective on fibromyalgia syndrome and its management. Baillieres Clin Rheumatol. 1994;8:957–993. [PubMed]
9. Paula J. Oliveira and Maria Emiília Costa (2012). Psychosocial Factors in Fibromyalgia: A Qualitative Study on Life Stories and Meanings of Living with Fibromyalgia, New Insights into Fibromyalgia, book edited by William S. Wilke, ISBN 978-953-307-407-8, Published: January 5, 2012 under CC BY 3.0 license.
10. Chang L. The association of functional gastrointestinal disorders and fibromyalgia. Eur J Surg Suppl. 1998;(583): 32–36 [PubMed]
11. Riedl A, Schmidtmann M, Stengel A, Goebel M, Wisser AS, Klapp BF, et al. Somatic comorbidities of irritable bowel syndrome: a systematic analysis. Psychosom Res 2008;64:573–82. [PubMed]
12. Wallace DJ, Hallegua DS. Fibromyalgia: the gastrointestinal link. Curr Pain Headache Rep 2004:8: 364–368. [PubMed]
13. Ruiz-Cabello P, Soriano-Maldonado A, Delgado-Fernandez M, Alvarez-Gallardo IC, Segura-Jimenez V, Estevez-Lopez F, et al. Association of dietary habits with psychosocial outcomes in women with fibromyalgia: the al-Andalus project. J Acad Nutr Diet 2016. November 24. Pil:S2212-2672(16)31190-X.
14. Slim M, Calandre EP, Rico-Villademoros F. An insight into the gastrointestinal component of fibromyalgia: clinical manifestations and potential underlying mechanisms. Rheumatol Int. 2015;35:433–44. doi: 10.1007/s00296-014-3109-9 [PubMed]
15. Fibromyalgia and food allergies-fibromyalgia. www.fibromyalgia-symptoms.org/effect-of-food-allergies-.
16. Goebel A, Buhner S, Schedel R, Lochs H, Sprotte G. Altered intestinal permeability in patients with primary fibromyalgia and in patients with complex regional pain syndrome. Rheumatology 2008;47:1223–1227. doi: 10.1093/rheumatology/ken140 [PubMed]
17. Pimentel M, Wallace D, Hallegua D, Chow E, Kong Y, Park S, et al. A link between irritable bowel syndrome and fibromyalgia may be related to findings on lactulose breath testing. Ann Rheum Dis 2004;63:450–452. doi: 10.1136/ard.2003.011502 [PMC free article] [PubMed]
18. Triadafilopoulos G, Simms RW, Goldenberg DL. Bowel dysfunction in fibromyalgia syndrome. Dig Dis Sci. 1991;36:59–64. [PubMed]
19. Wolfe F, Walitt BT, Katz RS, Lee YC, Michaud KD, Häuser W. Longitudinal patterns of analgesic and central acting drug use and associated effectiveness in fibromyalgia. Eur J Pain, 2013;17:581–586. doi: 10.1002/j.1532-2149.2012.00234.x [PubMed]
20. Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother. 2015;16:1347–1368. doi: 10.1517/14656566.2015.1047343 [PubMed]
21. Thieme K, Gracely RH. Are psychological treatments effective for fibromyalgia pain. Curr Rheumatol Rep 2009;11:443–450. [PubMed]
22. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res. 2002;53:865–871 [PubMed]
23. Torpy DJ, Chrousos GP. The three-way interactions between the hypothalamic-pituitary-adrenal and gonadal axes and the immune system. Baillieres Clin Rheumatol. 1996;10:181–198. [PubMed]
24. Database NHIR. Taiwan, http://nhird.nhri.org.tw/en/index.html (cited in 2015).
25. Chen HY, Lin CL, Kao CH. Does Migraine Increase the Risk of Glaucoma? A Population-Based Cohort Study. Medicine (Baltimore). 2016;95:e3670. [PMC free article] [PubMed]
26. Chen CH, Lin CL, Kao CH. Association between gallbladder stone disease and prostate cancer: A nationwide population-based study. Oncotarget. 2016;7:64380–64389. doi: 10.18632/oncotarget.9062 [PMC free article] [PubMed]
27. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. Arthritis Rheum. 1990;33:160–72. [PubMed]
28. Jacobson SA, Simpson RG, Lubahn C, Hu C, Belden CM, Davis KJ, et al. Characterization of fibromyalgia symptoms in patients 55–95 years old: a longitudinal study showing symptoms persistence with suboptimal treatment. Aging Clin Exp Res. 2015;27:75–82. doi: 10.1007/s40520-014-0238-7 [PMC free article] [PubMed]
29. Verim S, Batmaz I, Yazmalar L, Nas HC, Cevik R. Serum levels of neuron-specific enolase in patients with fibromyalgia syndrome: correlation with cognitive functions, quality of life and psychological state. J Back Musculoskelet Rehabil. 2016. June 30. [Epub ahead of print] [PubMed]
30. Bazzichi L, Giacomelli C, Consensi A, Atzeni F, Batticciotto A, Di Franco M, et al. One year in review 2016: fibromyalgia. Clin Exp Rheumatol 2016;34: S145–9. [PubMed]
31. Bellato E, Marini E, Castoldi F, Barbasetti N, Mattei L, Bonasia DE, et al. Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment. Pain Res Treat. 2012;2012:426130 doi: 10.1155/2012/426130 [PMC free article] [PubMed]
32. Staud R, Rodriguez ME. Mechanisms of disease: pain in fibromyalgia syndrome. Nat Clin Pract Rheumatol. 2006;2:90–98. doi: 10.1038/ncprheum0091 [PubMed]
33. Walker MM, Talley NJ. Review article: bacteria and pathogenesis of disease in the upper gastrointestinal tract—beyond the era of Helicobacter pylori. Aliment Pharmacol Ther. 2014;39:767–779. doi: 10.1111/apt.12666 [PubMed]
34. Zhang C, Zhang H, Yu L, Cao Y. Helicobacter pylori dwelling on the apical surface of gastrointestinal epithelium damages the mucosal barrier through direct contact. Helicobacter 2014;19:330–42. doi: 10.1111/hel.12138 [PubMed]
35. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11:1075–83. doi: 10.1016/j.cgh.2013.07.001 [PMC free article] [PubMed]
36. Yarandi SS, Peterson DA, Treisman GJ, Moran TH, Pasricha PJ. Modulatory Effects of Gut Microbiota on the Central Nervous System: How Gut Could Play a Role in Neuropsychiatric Health and Diseases. J Neurogastroenterol Motil. 2016;22:201–12. doi: 10.5056/jnm15146 [PMC free article] [PubMed]
37. Jong JCF, Berg PB, Tobi H, Berg LTW. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003;55:591–595. doi: 10.1046/j.0306-5251.2002.01770.x [PMC free article] [PubMed]
38. Calandre EP, Rico-Villademoros F, Slim M. An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opin Pharmacother 2015;16:1347–1368. doi: 10.1517/14656566.2015.1047343 [PubMed]
39. Liao CH, Chang CS, Chang SN, Muo CH, Lane HY, Sung FC, et al. The association of peptic ulcer and schizophrenia: a population-based study. J Psychosom Res. 2014;77:541–546. doi: 10.1016/j.jpsychores.2014.08.005 [PubMed]
40. Dall M, Schaffalitzky de Muckadell OB, Møller Hansen J, Wildner–Christensen M, Touborg Lassen A, Hallas J. Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors. Scand J Gastroenterol. 2011;46: 1039–1044. doi: 10.3109/00365521.2011.580100 [PubMed]
41. Itatsu T, Nagahara A, Hojo M, Miyazaki A, Murai T, Nakajima M, et al. Use of selective serotonin reuptake inhibitors and upper gastrointestinal disease. Intern Med. 2011;50:713–717. [PubMed]
42. Sanchez-Domingues B, Bullon P, Roman-Malo L, Marin-Aguilar F, Alcocer-Gomez E, Carrion AM, et al. Oxidative stress, mitochondrial dysfunction and inflammation common events in skin of patients with fibromyalgia. Mitochondrion. 2015;21:69–75. doi: 10.1016/j.mito.2015.01.010 [PubMed]
43. Meeus M, Nijs J, Hermans L, Goubert D, Calders P. The role of mitochondrial dysfunctions due to oxidative and nitrosative stress in the chronic pain or chronic fatigue syndromes and fibromyalgia patients: peripheral and central mechanisms as therapeutic targets? Expert Opin Ther Targets. 2013;17:1081–1089. doi: 10.1517/14728222.2013.818657 [PubMed]
44. Cordero MD, de Miguel M, Carmona-Lopez I, Bonal P, Campa F, Moreno-Fernandez AM. Oxidative stress and mitochondrial dysfunction in fibromyalgia. Neuro Endocrinol Lett 2010;31:169–173. [PubMed]
45. Calvino Fernandez M, Parra Cid T. H. Pylori and mitochondrial changes in epithelial cells. The role of oxidative stress. Rev Esp Enferm Dig. 2010;102:41–50. [PubMed]
46. Martin LF, Dean WL, Ratcliffe DJ, Suárez CP, Fry DE. Bioenergy metabolism of gastric mucosa during stress. Surgery. 1982;92:337–347. [PubMed]
47. Sato N, Kamata T, Kawano S, Abe H, Hagihara B. Oxidative and phosphorylative activities of the gastric mucosa of animal and humans in relation to the mechanism of stress ulcer. Biochim Biophys Acta. 1978;538:236–43 [PubMed]

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here